Cardiology
General Cardiology
Obstructive Sleep Apnea as a Risk Marker in Coronary Artery DiseaseSchäfer H.a · Koehler U.b · Ewig S.a · Hasper E.a · Tasci S.a · Lüderitz B.aaDepartment of Cardiology and Pulmonary Medicine, University of Bonn, Bonn, and bDepartment of Internal Medicine, University of Marburg, Marburg, Germany
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: March 07, 2000
Issue release date: February 2000
Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 3
ISSN: 0008-6312 (Print)
eISSN: 1421-9751 (Online)
For additional information: https://www.karger.com/CRD
Abstract
Study Objectives: Obstructive sleep apnea (OSA) is associated with a range of cardiovascular sequelae and increased cardiovascular mortality. The aim of our study was to assess the prevalence of OSA in patients with symptomatic angina and angiographically verified coronary artery disease (CAD). In addition, we analyzed the association of OSA and other coronary risk factors with CAD and myocardial infarction. Methods: Overnight non-laboratory-monitoring-system recordings for detection of OSA was performed in 223 male patients with angiographically verified CAD and in 66 male patients with exclusion of CAD. A logistic regression analysis was performed to assess associations between risk factors and CAD and myocardial infarction. Results: CAD patients were found to have OSA in 30.5%, whereas OSA was found in control subjects in 19.7%. The mean apnea/hypopnea index (AHI) was significantly higher (p < 0.01) in CAD patients (9.9 ± 11.8) than in control subjects (6.7 ± 7.3). Body-mass-index (BMI) was significantly higher in patients with CAD and OSA than in patients with CAD without OSA (28.1 vs. 26.7 kg/m2; p < 0.001). No significant difference was found with regard to other risk factors and left ventricular ejection fraction (LVEF) between both groups. Hyperlipidemia (OR 2.3; CI 1.3–3.9; p < 0.005) and OSA defined as AHI ≥20 (OR 2.0; CI 1.0–3.8, p < 0.05) were independently associated with myocardial infarction. Conclusions: There is a high prevalence of OSA among patients with angiographically proven CAD. OSA of moderate severity (AHI ≥20) is independently associated with myocardial infarction. Thus, in the care of patients with CAD, particular vigilance for OSA is important.
© 2000 S. Karger AG, Basel
Related Articles:
References
-
Guilleminault C: Clinical features and evaluation of obstructive sleep apnea; in Kryger MH, Roth T, Dement WC (eds): Principles and Practice of Sleep Medicine. Philadelphia, Saunders, 1994, pp 667–677.
- Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S: The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993;328:1230–1235.
- Strohl KP, Redline S: Recognition of obstructive sleep apnea. Am J Respir Crit Care Med 1996;154:279–289.
- Carlson JT, Hedner JA, Ejnell H, Peterson LE: High prevalence of hypertension in sleep apnea patients independent of obesity. Am J Respir Crit Care Med 1994;150:72–77.
- Working Group on OSA and Hypertension: Obstructive sleep apnea and blood pressure – What is the relationship? Blood Press 1993;2:166–182.
- Fletcher EC: The relationship between systemic hypertension and obstructive sleep apnea: Facts and theory. Am J Med 1995;98:118–128.
- He J, Kryger MH, Zorick FJ, Conway W, Roth T: Mortality and apnea index in obstructive sleep apnea. Chest 1988;94:9–14.
- Partinen M, Jamieson A, Guilleminault C: Long-term outcome for obstructive sleep apnea syndrome patients. Chest 1988;94:1200–1204.
- Penzel T, Amend G, Meinzer K, Peter JH, von Wichert P: MESAM: A heart rate and snoring recorder for detection of obstructive sleep apnea. Sleep 1990;13:175–182.
- Stoohs R, Guilleminault C: MESAM 4: An ambulatory device for the detection of patients at risk for obstructive sleep apnea syndrome (OSAS). Chest 1992;101:1221–1227.
- Redline S, Tosteson T, Boucher MA, Millman RP: Measurement of sleep-related breathing disturbances in epidemiologic studies. Assessment of the validity and reproducibility of a portable monitoring device. Chest 1991;100:1281–1286.
-
Koskenvuo M, Kapiro J, Partinen M, Langinvaino H, Sarna S, Heikkila K: Snoring as a risk factor for hypertension and angina pectoris. Lancet 1985;i:893–896.
-
Koskenvuo M, Kapiro J, Telakivi T, Partinen M, Heikkila K, Sarna S: Snoring as a risk factor for ischaemic heart disease and stroke in men. Br Med J 1987;294:16–19.
- Mooe T, Rabben T, Wiklund U, Franklin KA, Eriksson P: Sleep-disordered breathing in men with coronary artery disease. Chest 1996;109:659–663.
- Hung J, Whitford EG, Parsons RW, Hillman DR: Association of sleep apnoea with myocardial infarction in men. Lancet 1990;336:261–264.
- Weiss JW, Remsburg S, Garpestad E, Ringler J, Sparrow D, Parker JA: Hemodynamic consequences of obstructive sleep apnea. Sleep 1996;19:388–397.
- Carlson JT, Hedner J, Elam M, Ejnell H, Sellgren J, Wallin BG: Augmented resting sympathetic activity in awake patients with obstructive sleep apnea. Chest 1993;103:1763–1768.
- Gainer JL: Hypoxia and atherosclerosis: Re-evaluation of an old hypothesis. Atherosclerosis 1987;68:263–266.
- Crawford DW, Blankenhorn DH: Arterial wall oxygenation, oxyradicals and atherosclerosis. Atherosclerosis 1991;89:97–108.
-
Dean RT, Wilcox I: Possible atherogenic effects of hypoxia during obstructive sleep apnea. Sleep 1993;16(suppl 8):S15–S21.
- Schäfer H, Koehler U, Ploch T, Peter JH: Sleep-related myocardial ischemia and sleep structure in patients with obstructive sleep apnea and coronary heart disease. Chest 1997;111:387–393.
- Franklin KA, Nilsson JB, Sahlin C, Näslund U: Sleep apnoea and nocturnal angina. Lancet 1995;345:1085–1087.
- Shiomi T, Guilleminault C, Stoohs R, Schnittger I: Leftward shift of the interventricular septum and pulsus paradoxus in obstructive sleep apnea syndrome. Chest 1991;100:894–902.
- Schäfer H, Ewig S, Hasper E, Lüderitz B: Predictive diagnostic values of clinical assessment and non-laboratory-monitoring-system-recordings in patients with symptoms suggestive of obstructive sleep apnea syndrome. Respiration 1997;64:194–199.
- Javaheri S, Parker TJ, Wexler L, Michales SE, Stanberry E, Nishyama H, Roselle GA: Occult sleep-disordered breathing in stable congestive heart failure. Ann Intern Med 1995;122:487–492.
- De Olazabal JR, Miller MJ, Cook WR, Mithoefer JC: Disordered breathing and hypoxia during sleep in coronary artery disease. Chest 1982;82:548–552.
-
Andreas S, Schulz R, Haro W, Werner S, Kreuzer H: Schlafbezogene Atmungsstörungen bei Patienten mit koronarer Herzkrankheit. Dtsch med Wschr 1995;120:1533–1537.
- Mooe T, Rabben T, Wiklund U, Franklin KA, Eriksson P: Sleep-disordered breathing in women: Occurrence and association with coronary artery disease. Am J Med 1996;101:251–256.
Article / Publication Details
Published online: March 07, 2000
Issue release date: February 2000
Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 3
ISSN: 0008-6312 (Print)
eISSN: 1421-9751 (Online)
For additional information: https://www.karger.com/CRD
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Get Permission